| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | APOBEC1 |
| Uniprot No | P41238 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-236aa |
| 氨基酸序列 | MTSEKGPSTG DPTLRRRIEP WEFDVFYDPR ELRKEACLLY EIKWGMSRKI WRSSGKNTTN HVEVNFIKKF TSERDFHPSM SCSITWFLSW SPCWECSQAI REFLSRHPGV TLVIYVARLF WHMDQQNRQG LRDLVNSGVT IQIMRASEYY HCWRNFVNYP PGDEAHWPQY PPLWMMLYAL ELHCIILSLP PCLKISRRWQ NHLTFFRLHL QNCHYQTIPP HILLATGLIH PSVAWR |
| 分子量 | 28.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 冻干粉 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **文献名称**：ApoB mRNA editing is mediated by a site-specific endonuclease complex containing the APOBEC-1 protein
**作者**：B. Teng, C. F. Nathan, A. R. Blaner
**摘要**：该研究证实APOBEC-1是催化ApoB mRNA编辑的核心酶，需与互补因子(如ACF)形成复合体才能精准识别靶位点，揭示其编辑的分子机制及协同作用。
2. **文献名称**：Recombinant human APOBEC-1 catalyzes RNA editing in vitro
**作者**：K. Hirano, S. G. Young, R. V. Farese
**摘要**：通过重组表达人APOBEC-1蛋白，证明其体外可特异性编辑ApoB mRNA的C6666位点，突变关键结构域(如锌指区)会削弱编辑活性，为酶功能研究提供模型。
3. **文献名称**：APOBEC-1-mediated RNA editing in intestinal cells: potential role in carcinogenesis
**作者**：S. Anant, N. O. Davidson
**摘要**：探讨APOBEC-1在肠上皮细胞中的异常过表达可能导致非靶向RNA或DNA编辑，诱发遗传变异并参与肿瘤发生，提示其双重生物学效应及风险。
4. **文献名称**：APOBEC1: From lipid metabolism to therapeutic genome editing
**作者**：A. L. Sapiro, M. A. O’Connell
**摘要**：综述APOBEC-1的分子结构、生理功能及其工程化改造潜力，强调其作为精准基因编辑工具的优化策略(如融合脱氨酶结构域)及临床应用前景。
---
*注：上述文献信息为模拟示例，实际引用请参考真实数据库(如PubMed)中的权威来源。*
APOBEC-1 (apolipoprotein B mRNA editing enzyme catalytic subunit 1) is a cytidine deaminase central to RNA editing in humans. Discovered in the 1980s, it mediates site-specific C-to-U editing of apolipoprotein B (ApoB) mRNA in the small intestine and liver, converting the codon CAA (glutamine) to UAA (stop codon). This process generates two ApoB protein isoforms: full-length ApoB-100 (essential for lipid transport in LDL) and truncated ApoB-48 (critical for dietary fat absorption). APOBEC-1 functions as part of a multi-protein editosome complex, requiring auxiliary factors like A1CF (APOBEC-1 complementation factor) for target recognition.
Recombinant APOBEC-1. produced via genetic engineering, is widely used to study RNA editing mechanisms and its role in lipid metabolism. Its dysregulation has been linked to atherosclerosis and metabolic disorders. Unlike other APOBEC family members (e.g., APOBEC-3G involved in antiviral defense), APOBEC-1 exhibits restricted editing activity under physiological conditions. However, recombinant forms have been explored as programmable genome-editing tools due to their ability to induce targeted mutations, though off-target effects remain a challenge. Current research focuses on optimizing its specificity for therapeutic applications, including correcting genetic mutations or regulating lipid-related diseases. Despite potential, clinical translation requires further refinement to ensure precise control over editing activity.
×
